+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Marked Atherosclerosis in a Patient with Familiar Lecithin: Cholesterol Acyltransferase Deficiency Associated with End-Stage Renal Disease and Diabetes Mellitus

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Familial lecithin:cholesterol acyltransferase (LCAT) deficiency is a rare genetic disorder of the lipid metabolism caused by the absence of LCAT activity in plasma. It is not generally accompanied by atherosclerosis in spite of low high-density lipoprotein cholesterol levels nor by diabetes mellitus. However, reports of long-term follow-up or autopsy findings are rare, and the true incidence of atherosclerosis in LCAT deficiency is not clear. We report on the long-term observation of a patient with familial LCAT deficiency who developed renal failure, diabetes mellitus, and marked atherosclerosis. The patient died of sepsis from foot ulcers 7 years after starting hemodialysis and 13 years after the diagnosis. Marked atherosclerosis characterized by medial calcification in small arteries was observed at autopsy. The genesis of the atherosclerosis seemed to be on the basis of a combination of factors.

          Related collections

          Most cited references 1

          • Record: found
          • Abstract: not found
          • Article: not found

          Assay of total antioxidant capacity: comparison of four methods as applied to human blood plasma


            Author and article information

            Am J Nephrol
            American Journal of Nephrology
            S. Karger AG
            October 2001
            19 October 2001
            : 21
            : 5
            : 415-419
            aDivision of Nephrology and bDepartment of Pathology, Jichi Medical School, Tochigi, Japan
            46287 Am J Nephrol 2001;21:415–419
            © 2001 S. Karger AG, Basel

            Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

            Page count
            Figures: 5, Tables: 1, References: 20, Pages: 5
            Self URI (application/pdf): https://www.karger.com/Article/Pdf/46287
            Case Report


            Comment on this article